X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1304) 1304
humans (1021) 1021
female (718) 718
bridged-ring compounds - therapeutic use (606) 606
middle aged (457) 457
animals (447) 447
oncology (447) 447
male (420) 420
adult (387) 387
aged (379) 379
bridged-ring compounds - administration & dosage (375) 375
antineoplastic combined chemotherapy protocols - therapeutic use (362) 362
breast neoplasms - drug therapy (324) 324
bridged-ring compounds - pharmacology (318) 318
taxoids - therapeutic use (288) 288
taxoids - administration & dosage (275) 275
chemotherapy (272) 272
cancer (234) 234
pharmacology & pharmacy (232) 232
antineoplastic agents - therapeutic use (230) 230
treatment outcome (222) 222
mice (211) 211
breast cancer (198) 198
breast neoplasms - pathology (191) 191
paclitaxel (182) 182
rats (181) 181
taxoids (144) 144
docetaxel (134) 134
retrospective studies (128) 128
disease-free survival (121) 121
neoplasm staging (120) 120
bridged-ring compounds - chemistry (117) 117
prognosis (115) 115
bridged-ring compounds - adverse effects (114) 114
aged, 80 and over (113) 113
analysis (112) 112
drug resistance, neoplasm (107) 107
chemotherapy, adjuvant (106) 106
care and treatment (105) 105
therapy (105) 105
dose-response relationship, drug (103) 103
survival (102) 102
bridged bicyclo compounds - therapeutic use (101) 101
deoxycytidine - analogs & derivatives (98) 98
monoterpenes (98) 98
taxane (97) 97
research (95) 95
carcinoma (93) 93
anthracyclines - administration & dosage (92) 92
anthracyclines - therapeutic use (91) 91
ovarian neoplasms - drug therapy (89) 89
clinical trials as topic (88) 88
medicine & public health (88) 88
neoadjuvant therapy (87) 87
taxoids - adverse effects (86) 86
survival rate (83) 83
antineoplastic combined chemotherapy protocols - adverse effects (82) 82
time factors (82) 82
trial (82) 82
hematology, oncology and palliative medicine (79) 79
neoplasm metastasis (78) 78
cell line, tumor (74) 74
chemistry, medicinal (73) 73
drug administration schedule (73) 73
paeoniflorin (72) 72
abridged index medicus (70) 70
antineoplastic agents - pharmacology (70) 70
deoxycytidine - administration & dosage (70) 70
taxoids - pharmacology (69) 69
apoptosis (68) 68
expression (68) 68
lung neoplasms - drug therapy (68) 68
cisplatin (66) 66
survival analysis (66) 66
breast neoplasms - mortality (65) 65
anthracyclines (63) 63
health aspects (63) 63
antineoplastic agents - adverse effects (62) 62
article (62) 62
obstetrics & gynecology (62) 62
rats, sprague-dawley (62) 62
breast neoplasms - metabolism (61) 61
cisplatin - administration & dosage (61) 61
fluorouracil - administration & dosage (61) 61
follow-up studies (60) 60
metastasis (60) 60
ovarian cancer (60) 60
taxanes (60) 60
ramipril (57) 57
carcinoma, non-small-cell lung - drug therapy (56) 56
trastuzumab (56) 56
biochemistry & molecular biology (55) 55
receptor, erbb-2 - metabolism (55) 55
administration, oral (54) 54
cells (54) 54
adjuvant chemotherapy (53) 53
apoptosis - drug effects (53) 53
glucosides - pharmacology (53) 53
neoadjuvant chemotherapy (53) 53
antineoplastic agents - administration & dosage (51) 51
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1243) 1243
Japanese (39) 39
Russian (25) 25
Chinese (21) 21
German (14) 14
Italian (14) 14
French (12) 12
Spanish (3) 3
Bulgarian (1) 1
Finnish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 2, pp. 135 - 144
Journal Article
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 640 - 653
Summary Background Although trastuzumab plus chemotherapy is the standard of care for first-line treatment of HER2-positive advanced gastric cancer, there is... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | SUPPORTIVE CARE | WEEKLY PACLITAXEL | ONCOLOGY | 2ND-LINE CHEMOTHERAPY | IRINOTECAN | LEVEL | PLUS PACLITAXEL | HER2 | CANCER | DOCETAXEL | Follow-Up Studies | Febrile Neutropenia - chemically induced | Humans | Middle Aged | Male | Stomach Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Taxoids - therapeutic use | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Aged, 80 and over | Adult | Female | Stomach Neoplasms - chemistry | Adenocarcinoma - chemistry | Taxoids - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Bridged-Ring Compounds - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Anemia - chemically induced | Survival Rate | Thrombocytopenia - chemically induced | Stomach Neoplasms - drug therapy | Maytansine - therapeutic use | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Esophagogastric Junction | Gastrointestinal Hemorrhage - chemically induced | Retreatment | Intention to Treat Analysis | Bridged-Ring Compounds - adverse effects | Aged | Receptor, ErbB-2 - analysis | Trastuzumab | Adenocarcinoma | Medical research | Chemotherapy | Clinical trials | Medicine, Experimental | Metastasis | Esophageal cancer | Cancer | Analysis | Index Medicus
Journal Article
JAMA, ISSN 0098-7484, 05/2011, Volume 305, Issue 18, pp. 1873 - 1881
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2007, Volume 25, Issue 33, pp. 5210 - 5217
Journal Article
Breast Cancer Research, ISSN 1465-5411, 09/2015, Volume 17, Issue 1, pp. 129 - 129
Introduction: Obese breast cancer patients have worse prognosis than normal weight patients, but the level at which obesity is prognostically unfavorable is... 
BODY-MASS INDEX | POOLED ANALYSIS | EXPERIENCE | METAANALYSIS | ONCOLOGY | OVERWEIGHT | Body mass index | Anthracyclines | Breast cancer | Prognosis | Epidermal growth factor | Risk factors | Index Medicus
Journal Article
Cell Reports, ISSN 2211-1247, 05/2017, Volume 19, Issue 8, pp. 1669 - 1684
Although non-small cell lung cancer (NSCLC) patients benefit from standard taxane-platin chemotherapy, many relapse, developing drug resistance. We established... 
lung cancer | histone methylation | taxane-platin chemotherapy | JIB-04 | GSK-J4 | KDM | histone demethylases | demethylase inhibitors | Jumonji demethylases | drug resistance | CELLS | MELANOMA | THERAPY | CHEMOTHERAPY REGIMENS | MECHANISM | GENE-EXPRESSION | LEUKEMIA | MULTIDRUG-RESISTANCE | CELL BIOLOGY | Lung Neoplasms - drug therapy | Transcription, Genetic - drug effects | Taxoids - pharmacology | Benzazepines - adverse effects | Humans | Aminopyridines - adverse effects | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Gene Expression Profiling | Taxoids - therapeutic use | Hydrazones - adverse effects | Aminopyridines - therapeutic use | Carboplatin - therapeutic use | Hydrazones - therapeutic use | Jumonji Domain-Containing Histone Demethylases - antagonists & inhibitors | Bridged-Ring Compounds - pharmacology | Neoadjuvant Therapy | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Bridged-Ring Compounds - therapeutic use | Carcinoma, Non-Small-Cell Lung - genetics | Enzyme Inhibitors - pharmacology | Benzazepines - pharmacology | Pyrimidines - pharmacology | Enzyme Inhibitors - therapeutic use | Hydrazones - pharmacology | Disease-Free Survival | Drug Resistance, Neoplasm - genetics | Animals | Benzazepines - therapeutic use | Pyrimidines - therapeutic use | Aminopyridines - pharmacology | Pyrimidines - adverse effects | Cell Line, Tumor | Mice | Carcinoma, Non-Small-Cell Lung - drug therapy | Histones - metabolism | Carboplatin - pharmacology | Methylation | Jumonji Domain-Containing Histone Demethylases - metabolism | Drug Resistance, Neoplasm - drug effects | Index Medicus
Journal Article
Journal Article
Journal Article